Showing results (271-280 of 313) with videos related to
Sort By:
Pageof 32
Leukemia Research|April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemiaFrancis Giles, Srdan Verstovsek, Stefan Faderl, et al.Blood|December 4, 2008
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensKatherine I Lin, Constantine S Tam, Michael J Keating, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsCandida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.Pageof 32